Cargando…

Intratumoral CD8(+) T cells as a potential positive predictor of chemoimmunotherapy response in PD-L1-negative advanced gastric cancer patients: a retrospective cohort study

BACKGROUND: Previous studies have shown that PD-L1-positive advanced gastric cancer (GC) patients could achieve clinical benefit after receiving immune checkpoint inhibitors (ICI) in initial or subsequent therapy. A number of prospective studies such as Keynote-158 have demonstrated that PD-L1-negat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tong, Gangling, Zhu, Meiqin, Chen, Yaoxu, Wang, Shubo, Cheng, Boran, Wang, Shubin, Liao, Wangjun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9459198/ https://www.ncbi.nlm.nih.gov/pubmed/36092315 http://dx.doi.org/10.21037/jgo-22-644

Ejemplares similares

Intratumoral CD103(+)CD8(+) T cells predict response to neoadjuvant chemoimmunotherapy in advanced head and neck squamous cell carcinoma
por: Ren, Siqi, et al.
Publicado: (2023)

Enumeration And Characterization Of Circulating Tumor Cells And Its Application In Advanced Gastric Cancer
por: Cheng, Boran, et al.
Publicado: (2019)

Intratumoral PD-1(+)CD8(+) T cells associate poor clinical outcomes and adjuvant chemotherapeutic benefit in gastric cancer
por: Yu, Kuan, et al.
Publicado: (2022)

EBV(+) and MSI Gastric Cancers Harbor High PD-L1/PD-1 Expression and High CD8(+) Intratumoral Lymphocytes
por: De Rosa, Simona, et al.
Publicado: (2018)

SOX8 promotes tumor growth and metastasis through FZD6-dependent Wnt/β-catenin signaling in colorectal carcinoma
por: Li, Chen, et al.
Publicado: (2023)

MACC1 regulates PDL1 expression and tumor immunity through the c‐Met/AKT/mTOR pathway in gastric cancer cells
por: Tong, Gangling, et al.
Publicado: (2019)

Intratumoral CD103+ CD8+ T cells predict response to PD-L1 blockade
por: Banchereau, Romain, et al.
Publicado: (2021)

Immune activity score to assess the prognosis, immunotherapy and chemotherapy response in gastric cancer and experimental validation
por: Wu, Xuan, et al.
Publicado: (2023)

Complete response of metastatic gastric cancer to chemoimmunotherapy
por: Ina, Kenji, et al.
Publicado: (2017)

Hapten-enhanced overall survival time in advanced hepatocellular carcinoma by ultro-minimum incision personalized intratumoral chemoimmunotherapy
por: Gao, Feng, et al.
Publicado: (2015)

Prognostic impact of sarcopenia on immune-related adverse events in malignancies received immune checkpoint inhibitors: a systematic review and meta-analysis
por: Li, Shuluan, et al.
Publicado: (2021)

Hapten-enhanced therapeutic effect in advanced stages of lung cancer by ultra-minimum incision personalized intratumoral chemoimmunotherapy therapy
por: Yu, Baofa, et al.
Publicado: (2015)

Nanoparticles for Chemoimmunotherapy Against Triple-Negative Breast Cancer
por: Liu, Siyan, et al.
Publicado: (2022)

Macrophage-camouflaged epigenetic nanoinducers enhance chemoimmunotherapy in triple negative breast cancer
por: Gao, Tong, et al.
Publicado: (2023)

Safety and Efficacy of Neoadjuvant Chemoimmunotherapy in Gastric Cancer Patients with a PD-L1 Positive Status: A Case Report
por: Avgustinovich, Alexandra V., et al.
Publicado: (2023)

Trastuzumab with FLOT Regimen for the Perioperative Treatment of Resectable HER2 + Advanced Gastric Cancer: A Retrospective Study
por: Tong, Gangling, et al.
Publicado: (2020)

Intratumoral CXCR5(+)CD8(+)T associates with favorable clinical outcomes and immunogenic contexture in gastric cancer
por: Wang, Jieti, et al.
Publicado: (2021)

Impact of CD4 T cells on intratumoral CD8 T-cell exhaustion and responsiveness to PD-1 blockade therapy in mouse brain tumors
por: Khan, Saad M, et al.
Publicado: (2022)

Efficacy of Olanzapine-Triple Antiemetic Regimen in Patients with Gastrointestinal Tumor and High Risk of Chemotherapy-Induced Nausea and Vomiting Receiving Moderately Emetogenic Chemotherapy: A Retrospective Study
por: Wu, Xuan, et al.
Publicado: (2020)

Intratumoral CD8(+) Cytotoxic Lymphocyte Is a Favorable Prognostic Marker in Node-Negative Breast Cancer
por: Chen, Zonglin, et al.
Publicado: (2014)

Infiltration by Intratumor and Stromal CD8 and CD68 in Cervical Cancer
por: Dimitrova, Polina, et al.
Publicado: (2023)

Correction: Impact of CD4 T cells on intratumoral CD8 T-cell exhaustion and responsiveness to PD-1 blockade therapy in mouse brain tumors
Publicado: (2023)

CXCR6 is required for antitumor efficacy of intratumoral CD8(+) T cell
por: Wang, Binglin, et al.
Publicado: (2021)

Deletions on 9p21 are associated with worse outcomes after anti-PD-1/PD-L1 monotherapy but not chemoimmunotherapy
por: Ebot, Ericka M., et al.
Publicado: (2022)

PD-L1 and intratumoral immune response in breast cancer
por: Wang, Zhi-Qiang, et al.
Publicado: (2017)

Pathologic complete response to chemoimmunotherapy of an advanced gastric cancer patient with high PD-L1 expression, dMMR, and unique gut microbiota composition: A case report
por: Jiang, Hongpeng, et al.
Publicado: (2023)

High-level of intratumoral GITR+ CD4 T cells associate with poor prognosis in gastric cancer
por: Ke, Shouyu, et al.
Publicado: (2022)

Targeted delivery of liposomal chemoimmunotherapy for cancer treatment
por: Liu, Yusheng, et al.
Publicado: (2022)

Advances in Lipid-Based Nanoparticles for Cancer Chemoimmunotherapy
por: Wang, Tianqi, et al.
Publicado: (2021)

Circulating memory PD-1(+)CD8(+) T cells and PD-1(+)CD8(+)T/PD-1(+)CD4(+)T cell ratio predict response and outcome to immunotherapy in advanced gastric cancer patients
por: Liu, Jiang, et al.
Publicado: (2023)

TNF blockade uncouples toxicity from antitumor efficacy induced with CD40 chemoimmunotherapy
por: Stone, Meredith L., et al.
Publicado: (2021)

PD-L1(P146R) is prognostic and a negative predictor of response to immunotherapy in gastric cancer
por: Li, Qing, et al.
Publicado: (2022)

MAPK signaling regulates the efficacy of chemoimmunotherapy
por: Ghiringhelli, François
Publicado: (2022)

Intratumoral nanofluidic system enhanced tumor biodistribution of PD‐L1 antibody in triple‐negative breast cancer
por: Liu, Hsuan‐Chen, et al.
Publicado: (2023)

Skeletal Muscle Radio-Density Is an Independent Predictor of Response and Outcomes in Follicular Lymphoma Treated with Chemoimmunotherapy
por: Chu, Michael P., et al.
Publicado: (2015)

A study protocol of a randomized phase II trial of perioperative chemoimmunotherapy verses perioperative chemoimmunotherapy plus preoperative chemoradiation for locally advanced gastric (G) or gastroesophageal junction (GEJ) adenocarcinoma: the NeoRacing study
por: Zhou, Menglong, et al.
Publicado: (2022)

Trispecific natural killer cell nanoengagers for targeted chemoimmunotherapy
por: Au, Kin Man, et al.
Publicado: (2020)

CD74 and intratumoral immune response in breast cancer
por: Wang, Zhi-Qiang, et al.
Publicado: (2016)

Targeting ATAD3A-PINK1-mitophagy axis overcomes chemoimmunotherapy resistance by redirecting PD-L1 to mitochondria
por: Xie, Xiao-Qing, et al.
Publicado: (2023)

Immunoclassification characterized by CD8 and PD-L1 expression is associated with the clinical outcome of gastric cancer patients
por: Wang, Weili, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ratge923vfl34vspnerehmkf1l